Healthcare

Delivering solutions in M&A, Capital Raising, and Restructuring

Healthcare Investment Banking Group

Finding financial solutions across every sector of the healthcare ecosystem.

A full-service healthcare investment banking practice offering a best-in-class combination of deep sector knowledge, strong industry relationships, and broad product expertise.

Stifel’s Global Healthcare Investment Banking Group is comprised of 47 professionals covering all segments of the healthcare industry. The team, located in New York, San Francisco, London, Toronto, and Montreal, has substantial experience in assisting companies with all types of financing and M&A assignments. The Global Healthcare Group is dedicated to building long-term relationships with its clients through senior level attention. Since the formation of the Global Healthcare Group in Q4 2010, the team have helped raise over $79.1 billion for over 225 healthcare companies in over 440 transactions. Over the same period, members of the Global Healthcare Group have advised on over 105 announced M&A transactions, including over 30 cross-border assignments.

Our team provides clients with strategic advisory and capital-raising services designed to support growth companies and their investors during all stages of their development. We offer equity and debt capital markets services, including book running leading IPOs, follow-ons, and convertible note issuances. The Global Healthcare Group is supported by M&A advisory with extensive cross-border expertise, access to private capital markets through SPACs and 144A solutions, as well as activism defense and restructuring.

Areas of Expertise

Biopharma

The biopharma sector is advancing at an unprecedented pace, driven by innovation and growth from small to large companies across all stages of development and therapeutic areas. Stifel’s Biopharma team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our deep understanding of the biopharma landscape, and our extensive relationships and transaction experience.

Meet the Team

Healthcare Services

The healthcare services landscape is constantly shifting, driven by changes in regulations, reimbursement, and advancements in technology. Stifel’s Healthcare Services Team works to stay abreast of these changes and is ideally positioned to serve the needs of our clients in all types of financing and M&A assignments via relationships, recent mandates, and years of thought leadership across a broad range of healthcare sub-sectors including Alternate Site, Behavioral Health, Payor Services, Pharma Services, and Physician Groups.

Meet the Team

HealthTech

Technologies are rapidly advancing the automation of workflows across the healthcare ecosystem, the development and efficacy of treatments, and the way in which care is provided in-person and remotely. Stifel’s Healthcare Technology team brings a wealth of M&A and financing experience advising companies delivering software, digital health, data-driven, and technology-enabled solutions to providers, payors, pharmaceutical companies, and patients.

Meet the Team

Medtech

The Medtech sector is advancing at an unprecedented pace, driven by innovation and growth from small to large companies across all Medtech subsectors. Stifel’s Medtech team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our deep understanding of the Medtech landscape, and our extensive relationships and transaction experience.

Meet the Team

Tools & Diagnostics

The life science tools & diagnostics sector is transforming at amazing speeds. Enabled by a broad array of new technologies, our ability to better understand all facets of the human genome has improved exponentially; all the while being done at greater efficiency and dramatically reduced costs. This widening knowledge set is enabling faster and more productive drug discovery, disease diagnosis and AI-enabled prognostic clinical capabilities. Stifel’s Life Science Tools & Diagnostics team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our broad domain expertise, deep understanding of the competitive landscape, and our extensive relationships and transaction experience.

Meet the Team

The underlying fundamentals of the biopharma sector could not be more positive, in our view. Read our 2023 half year outlook for more on what’s driving the sector.

Learn More

Notable Transactions

$ 300,000,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Biopharma | November 2023

$ 245,000,000+

In-Licensing

Advisor to Licensee

Biopharma | November 2023

Mergers & Acquisitions

Advisor to Seller

HealthTech | November 2023

$ 100,000,000

Initial Public Offering

Joint Bookrunner

Biopharma | November 2023

$ 150,150,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Medtech | October 2023

$ 517,500,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Biopharma | October 2023

€ 154,430,010

Mergers & Acquisitions

Advisor to Seller

Medtech | October 2023

$ 100,000,000

Registered Direct

Joint Bookrunner

Biopharma | October 2023

$ 90,833,010

Mergers & Acquisitions

Advisor to Buyer

Biopharma | October 2023

Mergers & Acquisitions

Advisor to Seller

Healthcare | September 2023

$ 115,000,000

Confidentially marketed Follow-on Offering

Joint Bookrunner

Biopharma | September 2023

$ 250,070,000

Initial Public Offering

Joint Bookrunner

Biopharma | September 2023

$ 130,000,000

Follow-on Offering

Joint Bookrunner

Biopharma | July 2023

$ 345,057,500

Initial Public Offering

Joint Bookrunner

Biopharma | July 2023

£ 10,000,000

Equity Placing

Joint Bookrunner

Healthcare | July 2023

$ 120,000,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Biopharma | June 2023

$ 137,200,000

Follow-on Offering

Joint Bookrunner

Biopharma | June 2023

$ 200,000,000

Chapter 11 Restructuring

Investment Banker for Tricida

Biopharma | June 2023

£ 176,000,000

Mergers & Acquisitions

Financial Advisor

Medtech | April 2023

$ 460,000,000

Follow-on Offering

Joint Bookrunner

Biopharma | March 2023

$ 220,800,000

Initial Public Offering

Joint Bookrunner

Biopharma | February 2023

$ 20,300,000

PIPE

Sole Placement Agent and Nomad

Healthcare | February 2023

$ 100,000,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Medtech | February 2023

$ 227,843,965

Follow-on Offering

Joint Bookrunner

Biopharma | January 2023

Mergers & Acquisitions

Advisor to Seller

Healthcare | December 2022

$ 120,000,000

Convertible Notes

Left Bookrunner

Medtech | December 2022

$ 115,799,748

Registered Direct & PIPE

Joint Bookrunner & Joint Placement Agent

Biopharma | December 2022

$ 65,010,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Biopharma | December 2022

Mergers & Acquisitions

Advisor to Seller

Maritime Services, Healthcare Services | December 2022

$ 300,375,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Biopharma | December 2022

$ 64,000,000

Mergers & Acquisitions

Advisor to Seller

Tools & Diagnostics | November 2022

$ 850,000,000

Mergers & Acquisitions

Financial and Capital Markets Advisor

Biopharma | November 2022

$ 115,000,000

Follow-on Offering

Joint Bookrunner

Medtech | October 2022

£ 64,000,000

Convertible Bond & Follow-on Offering

Sole Bookrunner, Sole Placement Agent, Sole Broker and Nomad

Healthcare Services | October 2022

$ 58,079,577

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Biopharma | September 2022

$ 124,800,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Biopharma | September 2022

$ 260,000,000

Mergers & Acquisitions

Advisor to Seller

Healthcare Services | August 2022

$ 84,249,986

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Biopharma | August 2022

$ 143,893,750

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Medtech | August 2022

$ 862,500,000

Follow-on Offering

Lead Manager

Biopharma | August 2022

$ 104,500,000

Senior Secured Term Loan

Sole Placement Agent

Medtech | July 2022

$ 55,300,000

Exchange of Convertible Notes

Sole Bookrunner

Medtech | July 2022

$ 1,200,000,000

Mergers & Acquisitions

Advisor to Seller

Medtech | July 2022

$ 250,000,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

HealthTech | June 2022

C$ 34,511,565

Follow-on Offering

Joint Bookrunner

HealthTech | May 2022

£ 34,261,864

Follow-on Offering

Joint Bookrunner

Biopharma | May 2022

$ 108,000,000

Initial Public Offering

Joint Bookrunner

Biopharma | May 2022

Mergers & Acquisitions

Advisor to Seller

Healthcare Services | May 2022

$ 200,000,000

Initial Public Offering

Joint Bookrunner

Biopharma | April 2022

$ 230,000,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Biopharma | April 2022

€ 15,000,000

Follow-on Offering

Joint Global Coordinator and Joint Bookrunner

Healthcare | April 2022

$ 30,000,000

Convertible Bond and Equity Placing

Sole Financial Advisor and Sole Placement Agent

Medtech | March 2022

$ 230,000,000

Follow-on Offering

Joint Bookrunner

Biopharma | March 2022

$ 75,000,000

Confidentially Marketed Follow-on Offering

Left Bookrunner

Biopharma | March 2022

$ 40,000,000

Registered Direct

Financial Advisor

HealthTech | March 2022

$ 2,350,000,000

Senior Notes

Joint Bookrunner

HealthTech | February 2022

$ 100,000,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Biopharma | January 2022

$ 98,000,000

Initial Public Offering

Joint Bookrunner

Biopharma | January 2022

Mergers & Acquisitions

Advisor to Seller

Healthcare Services | December 2021

$ 52,325,000

Follow-on Offering

Joint Bookrunner

Biopharma | December 2021

C$ 65,000,000

Convertible Notes

Co-Lead Manager

HealthTech | November 2021

$ 172,500,000

SPAC IPO

Left Bookrunner

Biopharma | November 2021

$ 80,500,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Medtech | November 2021

$ 43,000,000

Private Placement

Lead Placement Agent

Biopharma | November 2021

$ 100,800,000

Follow-on Offering

Joint Bookrunner

Tools & Diagnostics | November 2021

$ 158,000,000

Mergers & Acquisitions

Capital Markets Advisor

HealthTech | November 2021

Mergers & Acquisitions

Advisor to Seller

Healthcare Services | November 2021

$ 230,000,000

Initial Public Offering

Joint Bookrunner

Healthcare Services | November 2021

$ 93,600,000

Initial Public Offering

Joint Bookrunner

Medtech | October 2021

$ 150,750,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Biopharma | October 2021

C$ 7,004,400

Follow-on Offering

Joint Bookrunner

Life Sciences & Healthcare | October 2021

$ 74,865,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Medtech | October 2021

$ 345,000,000

Follow-on Offering

Joint Bookrunner

Medtech | October 2021

$ 70,900,000

Mergers & Acquisitions

Advisor to Buyer

Medtech | October 2021

Mergers & Acquisitions

Advisor to Seller

Medtech | October 2021

$ 13,200,000

Follow-on Offering

Joint Bookrunner

Healthcare Services | September 2021

Mergers & Acquisitions

Advisor to Buyer

Medtech | September 2021

$ 1,000,000,000

Follow-on Offering

Joint Bookrunner

Biopharma | September 2021

$ 651,000,000

SPAC Merger

Capital Markets Advisor

Tools & Diagnostics | September 2021

Mergers & Acquisitions

Advisor to Buyer

Biopharma | August 2021

$ 212,000,000

SPAC Merger & PIPE

Capital Markets Advisor

Biopharma | August 2021

$ 355,810,000

Initial Public Offering

Joint Bookrunner

Biopharma | August 2021

$ 84,333,337

Initial Public Offering

Joint Bookrunner

Biopharma | July 2021

$ 230,000,000

Initial Public Offering

Joint Bookrunner

Tools & Diagnostics | July 2021

Mergers & Acquisitions

Advisor to Seller

Biopharma | July 2021

£ 17,000,000

Initial Public Offering

Sole Global Coordinator, Joint Bookrunner & Nomad

HealthTech | July 2021

$ 174,560,000

Initial Public Offering

Joint Bookrunner

Biopharma | July 2021

$ 180,132,080

Initial Public Offering

Joint Bookrunner

Tools & Diagnostics | July 2021

$ 62,675,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Medtech | July 2021

$ 100,190,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Biopharma | July 2021

$ 350,000,000

Follow-on Offering

Joint Bookrunner

Biopharma | July 2021

$ 97,807,500

Initial Public Offering (U.S. Nasdaq)

Joint Bookrunner

Medtech | July 2021

$ 181,500,000

Mergers & Acquisitions

Advisor to Seller

Biopharma | July 2021

$ 160,000,000

Initial Public Offering

Joint Bookrunner

Biopharma | June 2021

$ 160,000,000

Initial Public Offering

Joint Bookrunner

Biopharma | June 2021

$ 80,000,000

Follow-on Offering

Left Bookrunner

Entertainment | June 2021

Mergers & Acquisitions

Advisor to Seller

Healthcare Services | June 2021

$ 366,000,000

Follow-on Offering

Co-Manager

Medtech | April 2021

$ 98,325,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Biopharma | April 2021

$ 100,912,500

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Medtech | April 2021

$ 287,500,000

Follow-on Offering

Joint Bookrunner

Biopharma | April 2021

$ 646,875,000

Follow-on Offering

Joint Bookrunner

Tools & Diagnostics | April 2021

$ 550,000,000

Convertible Senior Notes

Joint Bookrunner

Biopharma | April 2021

$ 103,500,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Biopharma | March 2021

$ 50,652,000

Confidentially Marketed Follow-on Offering

Left Bookrunner

Biopharma | March 2021

$ 30,000,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Biopharma | March 2021

$ 48,000,000

Follow-on Offering

Joint Bookrunner

Biopharma | March 2021

$ 56,000,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Biopharma | March 2021

$ 55,000,000

PIPE

Joint Placement Agent

Biopharma | March 2021

$ 218,500,000

Initial Public Offering

Joint Bookrunner

Biopharma | March 2021

$ 115,000,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

HealthTech | March 2021

$ 160,425,000

Follow-on Offering

Joint Bookrunner

Biopharma | March 2021

$ 138,250,000

Convertible Notes

Sole Bookrunner

Medtech | March 2021

$ 90,000,000

Has Invested in

Advisor to Squadron

Medtech | March 2021

$ 222,250,000

Follow-on Offering

Joint Bookrunner

HealthTech | February 2021

$ 60,000,000

Follow-on Offering

Joint Bookrunner

HealthTech | February 2021

$ 2,200,000,000

Senior Notes

Co-Manager

Healthcare Services | February 2021

$ 150,000,000

Follow-on Offering

Joint Bookrunner

HealthTech | February 2021

$ 42,000,000

Confidentially Marketed Follow-on Offering

Sole Bookrunner

Medtech | February 2021

$ 264,500,000

Initial Public Offering

Joint Bookrunner

Biopharma | February 2021

$ 203,439,942

Initial Public Offering

Joint Bookrunner

Biopharma | February 2021

$ 117,000,000

Initial Public Offering

Joint Bookrunner

Biopharma | February 2021

SPAC Merger & PIPE

Capital Markets Advisor

Biopharma | February 2021

£ 40,000,000

PIPE

Sole Placement Agent

Biopharma | February 2021

$ 74,500,000

Confidentially Marketed Follow-on Offering

Left Bookrunner

Biopharma | February 2021

$ 70,000,000

Private Placement

Joint Placement Agent

HealthTech | February 2021

$ 129,375,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Biopharma | January 2021

$ 168,000,000

Follow-on Offering

Joint Bookrunner

Biopharma | January 2021

$ 103,500,000

Follow-on Offering

Joint Bookrunner

Biopharma | January 2021

$ 264,000,000

Follow-on Offering

Joint Bookrunner

Healthcare Services | January 2021

$ 555,450,000

Initial Public Offering

Joint Bookrunner

Biopharma | December 2020

$ 149,500,000

Initial Public Offering

Joint Bookrunner

Tools & Diagnostics | December 2020

$ 200,000,000

Follow-on Offering

Joint Bookrunner

Biopharma | December 2020

$ 345,080,500

Follow-on Offering

Joint Bookrunner

Biopharma | December 2020

$ 312,225,000

Follow-on Offering

Joint Bookrunner

Tools & Diagnostics | December 2020

$ 750,000,000

Follow-on Offering

Joint Bookrunner

Tools & Diagnostics | December 2020

$ 277,725,000

Initial Public Offering

Joint Bookrunner

Biopharma | December 2020

$ 1,863,000,000

Initial Public Offering

Joint Bookrunner

Tools & Diagnostics | November 2020

$ 81,176,464

Initial Public Offering

Joint Bookrunner

Biopharma | November 2020

$ 345,000,000

Initial Public Offering

Lead Manager

Medtech | October 2020

$ 104,796,260

Initial Public Offering

Left Bookrunner

Medtech | October 2020

$ 1,898,938,296

Mergers & Acquisitions

Joint Financial Advisor

Biopharma | October 2020

$ 2,128,500,000

Initial Public Offering

Lead Manager

Medtech | October 2020

$ 200,000,000

Convertible Notes

Joint Bookrunner

Biopharma | September 2020

$ 277,761,104

Initial Public Offering

Joint Bookrunner

Biopharma | September 2020

$ 267,696,966

Initial Public Offering

Joint Bookrunner

Biopharma | September 2020

$ 963,470,000

Follow-on Offering

Joint Bookrunner

Biopharma | August 2020

$ 140,000,000

Mergers & Acquisitions

Advisor to Seller

Biopharma | August 2020

$ 140,000,000

Mergers & Acquisitions

Advisor to Seller

Biopharma | August 2020

$ 135,000,000

Mergers & Acquisitions

Advisor to Buyer

Biopharma | July 2020

$ 445,000,000

PIPE

Financial Advisor

Biopharma | July 2020

$ 209,000,000

Initial Public Offering

Joint Bookrunner

Biopharma | July 2020

$ 80,000,000

PIPE

Lead Placement Agent

Biopharma | July 2020

$ 120,000,000

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Biopharma | July 2020

$ 39,054,798

Mergers & Acquisitions

Advisor to Buyer

Medtech | April 2020

$ 79,347,051

Confidentially Marketed Follow-on Offering

Joint Bookrunner

Biopharma | March 2020

$ 125,000,000

Strategic Financing Agreement

Financial Advisor

Biopharma | February 2019

Mergers & Acquisitions

Advisor to Seller

Biopharma | September 2018

Currency volume represents full credit to each underwriter. All transaction announcements appear as a matter of record only. Stifel collectively refers to Stifel, Nicolaus & Company, Incorporated and other affiliated broker-dealer subsidiaries of Stifel Financial Corp.